Browse > Article
http://dx.doi.org/10.4333/KPS.2004.34.6.521

Bioequivalence of Tagamet Tablet to Sinil CIMETIDINE Tablet (cimetidine 400 mg)  

Yoon, Mi-Kyeong (College of Pharmacy, Chung-Ang University)
Lee, Byoung-Moo (College of Pharmacy, Chung-Ang University)
Lee, Sung-Jae (College of Pharmacy, Chung-Ang University)
Kim, Sun-Kyu (College of Pharmacy, Chung-Ang University)
Lee, Jae-Hwi (College of Pharmacy, Chung-Ang University)
Choi, Young-Wook (College of Pharmacy, Chung-Ang University)
Publication Information
Journal of Pharmaceutical Investigation / v.34, no.6, 2004 , pp. 521-527 More about this Journal
Abstract
Cimetidine is a histamine $H_2-receptor$ antagonist, used for the treatment of endoscopically or radiographically comfirmed duodenal ulcer, pathologic GI hypersecretory conditions, and active, benign and gastric ulcer. Simple method for determining cimetidine in human plasma has been developed and validated. The analytical procedure for cimetidine showed a linear relationship in the concentration ranges from $0.05\;to\;5\;{\mu}g/ml$. Coefficient of variance (CV, %) for intraday and interday validation and relative error (RE, %) were less than ${\pm}15%$. Based on this analytical method, the bioequivalence of two cimetidine 400 mg tablets, reference (Tagamet 400 mg) and test drug (Sinil CIMETIDINE 400 mg) was evaluated according to the guidelines set by the Korea Food and Drug Administration (KFDA). Release of cimetidine from the tablets in vitro was tested using KP VIII Apparatus II with various dissolution media (pH 1.2, 4.0, 6.8 buffer solutions and water). Twenty-four healthy volunteers, $21.38{\pm}1.86$ years in age and $68.71{\pm}8.68\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was performed. After oral administration of a tablet containing 400 mg of cimetidine, blood samples were taken at predetermined time intervals and concentrations of cimetidine in plasma were determined using HPLC equipped with UV detector. The dissolution profiles of the two tablet formulations were very similar at all dissolution media. In addition, pharmacokinetic parameters such as $AUC_t$ and $C_{max}$ were calculated and ANOVA was employed for the statistical analysis of parameters. The results were revealed that the differences in $AUC_t$ and $C_{max}$ between the two tablets were 4.17 % and 0.97% respectively. At 90% confidence intervals, the differences in these parameters were also within ${\pm}20%$. All of the above mentioned parameters have met the criteria of KFDA guidelines for bioequivalence, indicating that the test drug tablet (Sinil CIMETIDINE tablet) is bioequivalent to Tagamet 400 mg tablet.
Keywords
Cimetidine; Tagamet; Sinil CIMETIDINE; Bioequvalence; HPLC;
Citations & Related Records
연도 인용수 순위
  • Reference
1 J. Hempenius et al., High-throughput solid-phase extraction for the detennination of cimetidine in human plasma, Journal of Chromatography. B, 714, 361-368 (1998)
2 USP 24, General Information <1090> In VIvo Bioequivalene Guidances; Cimetidine Tablets - In VIvo Bioequivalence and In VItro Dissolution Testing, 2069-2070 (1999)
3 Jiunn H. Lin, Pharmacokinetic and pharmacodynamic properties of histamine Hrreceptor antagonists, Clinical Pharmacokinetics, 20, 218-239 (1991)   DOI   ScienceOn
4 식품의약품안전청 고시 제2002-60호 (2002. 11. 22). 생물학적동등성시험기준.
5 Review of in vivo bioequivalence studies, dissolution data and waiver request, FDA website, CDER application Number 074568 (1995)
6 S.G. Park, J.Y. Lee, S.U. Choi, M.K. Yoon, J. Lee and yw. Choi, Statistical Interpretation of Bioequivalence in 2 x 2 Crossover Design with Missing Observations, The Journal of Korean Pharmaceutical Sciences, 34, 215-222 (2004)
7 A.M. Rustum and N.B. Hoffman, Liquid chromatographic detennination of cimetidine in whole blood and plasma by using short polymeric phase column, Journal of the Association of Official Agricultural Chemists, 71, 519-522 (1988)
8 Y.J. Lee, Y.G. Kim, M.G. Lee, S.J. Chung, M.H. Lee and C.K. Shim, Analysis of bioequivalence study using logtransformed model, Yakhakhoeji, 44, 308-314 (2000)
9 H.I. Patel, Analysis of incomplete data in a two-period crossover design with reference to clinical trials, Biometrika, 72,411-418 (1985)   DOI   ScienceOn